Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

NCT03924882 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT03924882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03924882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 2
Overall status
Unknown status
Start date
April 25, 2019
Completion date
April 25, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer